Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results
01:45pm, Thursday, 17'th Apr 2025
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, establishing leadership in obesity treatment. Orforglipron offers advantages over co
Lilly reports positive phase 3 trial results for GLP-1 pill
10:29am, Thursday, 17'th Apr 2025
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest results from Eli Lilly's efforts to develop a GLP-1 pill.
Eli Lilly's Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes Trial, Stock Soars
07:58am, Thursday, 17'th Apr 2025
Eli Lilly And Co LLY stock is trading higher on Thursday after the U.S. healthcare giant reported topline Phase 3 results from ACHIEVE-1 trial of orforglipron compared to placebo in adults with type 2
Eli Lilly's experimental GLP-1 pill met its study goals, helping diabetes patients lower blood sugar and even lose weight
06:45am, Thursday, 17'th Apr 2025
The drug helped lower patients' blood sugar and reduce their weight by an average of 16 pounds.
Orforglipron is the first small molecule GLP-1 to successfully complete a Phase 3 trial, lowering A1C by an average of 1.3% to 1.6% across doses The investigational once-daily oral pill reduced weight
RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption
07:00am, Wednesday, 16'th Apr 2025
GLP-1 comparable efficacy: Opaganib's positive results, newly published in the journal Diabetes, Metabolic Syndrome and Obesity, demonstrated weight loss and improved metabolic markers on par with sem
With No Titration, Demonstrated Compelling Maximum Weight Loss of 6.3% and Mean Weight Loss of 4.3% at Day 26 at 32 mg Dose (p=0.0005) Demonstrated Strong Signal of GLP-1R Efficacy with Maximum Lowe
Global Partners Announces Cash Distribution on Series B Preferred Units
08:30am, Monday, 14'th Apr 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (the “Partnership”) today announced that the Board of Directors (the “Board”) of its general partner, Global GP LLC, has declare
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
09:10am, Thursday, 03'rd Apr 2025
Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss Kelowna, British Columbia – April 3, 2025 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the
Lexaria's Human GLP-1 Study #5 Begins Dosing
09:05am, Wednesday, 02'nd Apr 2025
Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide Study will investigate Pharmacokinetics and Safety KELOWNA, BC / ACCESS Newswire / April
Labor Smart Targets GLP-1 Market with Functional Gummies - Pre-Orders Begin April 7th
08:00am, Tuesday, 01'st Apr 2025
JACKSON, WY / ACCESS Newswire / April 1, 2025 / Labor Smart, Inc. (OTC PINK:LTNC), through its newest subsidiary Elevate Health and Wellness Nutritionals, is entering the fast-growing GLP-1 weight los
Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation
07:00am, Tuesday, 01'st Apr 2025
New REVEAL-1 study results show early signs of weight maintenance after GLP-1 discontinuation REMAIN-1 pivotal study now more than 50% enrolled; midpoint data analysis anticipated in Q3 2025 BURLINGTO
Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update
04:05pm, Monday, 31'st Mar 2025
- Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 -
The Vitamin Shoppe® Unveils First-of-its-Kind Supplement Line Formulated for GLP-1 Users
08:35am, Monday, 31'st Mar 2025
The d ietitian formulated, doctor-approved GLP-1 Support from Whole Health Rx™ by The Vitamin Shoppe® range of supplements delivers comprehensive nutritional solutions for individuals on GLP-1 wei
ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today announced a new strategic direction to develop and deploy
